Related Experiment Video
Updated: Aug 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Drug treatment of atrial fibrillation]
1Städtisches Klinikum, München GmbH, Klinikum Bogenhausen.
Insights
Effective atrial fibrillation treatment requires ruling out causes and balancing rhythm control against risks. Beta blockers are key for recurrence prevention, with other drugs used based on patient health.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) necessitates ruling out treatable causes before initiating specific therapies.
- Individualized risk-benefit assessments are crucial for anti-arrhythmic therapy versus maintaining sinus rhythm.
- Alternative treatment strategies should be considered alongside pharmacotherapy.
Purpose of the Study:
- To outline current recommendations for managing atrial fibrillation.
- To discuss the choice between rate control and rhythm control strategies.
- To review pharmacological options for AF recurrence prevention and potential future therapies.
Main Methods:
- Review of current guidelines and literature on atrial fibrillation management.
- Analysis of treatment strategies based on patient demographics (age) and symptoms.
- Evaluation of drug classes for rate control, rhythm control, and recurrence prevention.
Main Results:
- Rate control is recommended for asymptomatic, particularly elderly, patients.
- Rhythm control is preferred for younger, symptomatic patients.
- Beta blockers are first-line for recurrence prevention; Class IC agents (no structural heart disease) or amiodarone (with structural heart disease) may be considered.
Conclusions:
- Treatment decisions for atrial fibrillation must be individualized, considering risks and benefits.
- Pharmacotherapy choices depend on patient characteristics and presence of structural heart disease.
- Future AF management likely involves combined pharmacotherapy and non-drug interventions.
Abstract:
Before initiating specific treatment of atrial fibrillation treatable causes must first be reliably ruled out. Furthermore, the chances of maintaining a sinus rhythm must be individually weighed against the potential complications and risks of an anti-arrhythmic therapy, and also alternative strategies considered. Today, rate control is recommended in the case of asymptomatic patients, in particular in the elderly, while rhythm control is the strategy of choice in younger, symptomatic patients. For recurrence prevention, beta blockers are the first-choice drugs. In patients with no structural heart disease, class IC antiarrhythmic agents, in those with structural heart disease only amiodarone, may be considered. Promising new additive therapeutic approaches are ACE-inhibitors and AT-II receptor antagonists. In the future, combinations of pharmacotherapy and non-drug treatments will help to improve the treatment of atrial fibrillation.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias VI: Management of Dysrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Venous Thrombosis III: Interprofessional Care
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Aortic Regurgitation III: Medical Management

